Philip Siberg
Chief Executive Officer
Year-End Report 2025 presentation
Philip Siberg, CEO of Senzime, presented the Year-end report for 2025 on February 18, 9:00 CET.
Presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Senzime launches TetraCom connectivity platform enabling universal transmission of anesthesia data
Regulatory PR
Senzime Q4 2025: Accelerated growth and continued clear path to profitability
Regulatory PR
Senzime secures credit line facility of 50 MSEK
Financial info Jan - Dec 2025
January-December 2025: Accelerated growth and continued clear path towards profitability
2025 was the year we increased the growth rate and exceeded SEK 100 million in sales. We won a number of major strategic deals, consolidated our leading market position and now have a clearly defined path to profitability ahead of us. Growth in 2025 amounted to 90 percent in constant currencies, corresponding to sales of SEK 111 million. In actual currencies, growth amounted to 78 percent. Behind the increase are even more hospital contracts won and increased utilization rates among existing customers.
The fourth quarter ended the year strong with 125 percent growth in constant currencies and 102 percent in actual currencies.
104
Net sales, MSEK
78
Net sales, % increase
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.